))
Hear from academic and industry experts sharing insider insights, information and trend forecasts for the cell and gene therapy industry. “Commercializing Living Therapies with CCRM” is brought to you by CCRM, a leader in developing, manufacturing and commercializing regenerative medicine-based technologies, and cell and gene therapies. Questions / comments? email: podcast@ccrm.ca.
…
continue reading
1
Biomanufacturing redefined: The role of AI and robotics in producing cell and gene therapies
34:59
Featuring: Christopher P. Boone, PhD, Group Vice President, Research Services, Health & Life Sciences, Oracle Kenneth L. Harris, Chief Strategy Officer and Head of AI, OmniaBio Inc. *** We are excited to share the first episode in the fourth season (!) of Commercializing Living Therapies with CCRM. A big thanks to all our listeners. In this episode…
…
continue reading
Featuring: Jacki Jenuth, PhD, Partner and COO, Lumira Ventures Robin Quirk, PhD MBA, Vice President, Technology Sourcing and Venture Development, CCRM *** In this episode, we explore the dynamics of venture capital (VC) and company creation with Jacki Jenuth, Partner and COO, Lumira Ventures, and Robin Quirk, Vice President, Technology Sourcing and…
…
continue reading
Featuring: Michael Rosu-Myles, PhD, Executive Director, Health Canada Josephine Lembong, PhD, Senior Manager, Science and Industry Affairs, Alliance for Regenerative Medicine *** Currently, there are more than 2,000 cell and gene therapies in clinical trials worldwide. With a goal of ensuring that safe and quality products are approved for use by p…
…
continue reading
Featuring: Sonia Sennik, Executive Director, Creative Destruction Lab Glenn MacLean, Director, Technology Sourcing and Venture Development, CCRM *** In many science-oriented fields, including regenerative medicine and advanced therapies, researchers and company founders often require additional support and expertise to successfully commercialize th…
…
continue reading
Featuring: Matthew Durdy, Chief Executive Officer, Cell and Gene Therapy Catapult Michael May, PhD, President and Chief Executive Officer, CCRM *** Public-private partnerships are collaborations between government agencies and private-sector companies. In this interview, Matthew Durdy, CEO, Cell and Gene Therapy Catapult, and Michael May, President…
…
continue reading
Featuring: Matthew Miller, B.M.Sc., PhD, Director, Michael G. DeGroote Institute for Infectious Disease Research; Co-Director, Canadian Pandemic Preparedness Hub (CP2H), McMaster University Patrycja Thompson, PhD, Director, Strategy & Operations, the Canadian Hub for Health Intelligence & Innovation in Infectious Diseases (HI3), University of Toron…
…
continue reading
1
From code to cure: Exploring the synergies of artificial intelligence and regenerative medicine
33:23
Featuring: Mamatha Bhat MD, MSc, PhD, FRCPC Hepatologist & Co-Lead of Transplant AI initiative (TAI), Ajmera Transplant Program Scientist, Toronto General Hospital Research Institute, University Health Network Associate Professor, Division of Gastroenterology & Hepatology Director, Clinician-Scientist Training Program (CSTP), Department of Medicine…
…
continue reading
Featuring: Tom Whitehead, Co-Founder, Emily Whitehead Foundation. Courtney Horvath, PhD, Global Head of Strategy, Planning & Operations, Translational Medicine, Novartis. In this episode, we hear from two parents who supported their children through cancer treatments. Listeners will hear their unflinching accounts of what the children went through,…
…
continue reading
Featuring: Dr. Joerg Krueger, Medical Director, CAR T-Cell Program, The Hospital for Sick Children. Dr. Bruce Levine, Barbara and Edward Netter Professor in Cancer Gene Therapy, University of Pennsylvania Perelman School of Medicine. Our guests discuss the future of CAR T-cell therapies, in a conversation covering autologous and allogeneic CAR T th…
…
continue reading
Featuring: Mark Taylor, Director of Commercialization, University Health Network Dr. Irja Elliott Donaghue Technical & IP Specialist and Patent Agent, Notch Therapeutics In the past, there was little evidence to challenge the idea that if a therapeutics developer did not hold a patent, it did not have anything to commercialize. In this episode, gue…
…
continue reading
Featuring: Dr. Dolores Baksh, CEO of TAAV Biomanufacturing Solutions Susan Nichols, Chief Business Officer at ViroCell Biologics As the cell and gene therapy industry continues to grow rapidly, Dolores Baksh and Susan Nichols emphasize the importance of nurturing a new workforce equipped with the skills to pivot and persevere—crucial qualities for …
…
continue reading
Featuring: Dr. Lise Munsie, Vice President, iPSC Technology Platform, CCRM Dr. Stephen Sullivan, Programme Manager, Global Alliance for iPSC Therapies (GAiT) Drs. Lise Munsie and Stephen Sullivan explore some of the biggest challenges that will need to be addressed to unlock the potential of induced pluripotent stem cells (iPSCs), from regulatory i…
…
continue reading
Featuring: Dr. Qasim Rafiq, Associate Professor in Cell and Gene Therapy Bioprocess Engineering, University College London (UCL) Dr. Christine Allen, Vice-President, Ecosystem Development, adMare BioInnovations Drs. Christine Allen and Qasim Rafiq offer insight on how to train and retain tomorrow’s cell and gene therapy (CGT) workforce in a very co…
…
continue reading
How will Canada’s health care system pay for cell and gene therapy cures? Featuring: Dr. Chris McCabe, CEO and Executive Director, Institute of Health Economics Robert Woolstencroft, Senior Director and Head, Market Access and Reimbursement, Gilead Sciences Canada Our guests tackle the complex question of how therapy developers working at the cutti…
…
continue reading
Examining the role ethical considerations and regulatory frameworks will play in regenerative medicine’s future. Featuring: Prof. Bartha Maria Knoppers, Canada Research Chair in Law and Medicine, and Director of the Centre of Genomics and Policy, Faculty of Medicine, McGill University Siofradh McMahon, Director, Clinical Translation and Regulatory …
…
continue reading
Looking to the future of synthetic biology in cell and gene therapies. Featuring: Dr. George Church, Professor of Genetics, Harvard Medical School Dr. Peter Zandstra C.M., Director and Professor, School of Biomedical Engineering, University of British Columbia Hear from Drs. Church and Zandstra about the promise of the emerging synthetic biology fi…
…
continue reading
Manufacturing and supply chain issues in cell and gene therapies. Featuring: Dr. Anthony Davies, Founder and CEO, Dark Horse Consulting Rob Jones, Vice President, Global Bioservices, Cryoport Systems It’s no secret that supply chain and manufacturing are crucial to the cell and gene therapy industry, but now the whole world seems to be paying atten…
…
continue reading
The business of regenerative medicine and investment. Featuring: Dr. Cynthia Lavoie, President and Chief Investment Officer, CCRM Enterprises Geoff MacKay, President and CEO, AVROBIO Dr. Lavoie and Mr. MacKay share what brought them to regenerative medicine in the first place, why investors are bullish about the field, and which trends they have an…
…
continue reading
How can the regenerative medicine community create broader societal awareness? Featuring: Dr. Janet Rossant, President and Scientific Director, Gairdner Foundation Dr. Phil Vanek, Chief Technology Officer, Gamma Biosciences Drs. Rossant and Vanek discuss public awareness of cell and gene therapies, the importance of improving it, and how confusing …
…
continue reading
